The purpose of this study was to evaluate the effect of peanut oral immunotherapy on food-specific quality of life.

The study enrolled 100 children, 5 to 18 years of age, with suspected or known peanut allergy based on history, elevated specific immunoglobulin E to peanut, and skin testing. If a subject did not meet inclusion criteria (eg, skin-prick wheal ≤7 mm, no anaphylaxis, reaction more than 1 year ago, or peanut immunoglobulin E <15), a single blind food challenge was performed to confirm allergy before enrollment.

A desensitization protocol was performed starting with 0.1 mg of peanut protein and doubling in the amount given every 30 minutes to a maximum of 6 mg on day 1 (maximum cumulative dose of 12 mg). On day 2, subjects returned and were given the maximum tolerated dose from the previous day. If tolerated, subjects were discharged with instructions to continue this daily dosing...

You do not currently have access to this content.